The outcomes were post-cessation weight gain and abstinence rates obtained either through self-report or a carbon monoxide breath test. Less Weight Gain. People taking GLP-1 RAs gained a mean of 2 ...

As Miami-based Veru continues development of its enobosarm to prevent muscle wasting in patients being treated for obesity, ...

The delay in gastric emptying caused by GLP-1 RAs is modest at worst, indicating that patients may not need to discontinue these medications before a procedure, a meta-analysis showed.

In June 2023, the American Society of Anesthesiologists released initial guidelines for GLP-1 users, instructing them to hold usage of the medication leading up to procedures requiring anesthesia. New ...

The researchers found that stopping Ozempic 5 days, 3 days, and 1 day prior to surgery was an independent risk factor for delayed emergence from anesthesia (odds ratios, 1.59, 1.84, and 2.23 ...

Key Takeaways. GLP-1 RAs and SGLT2 inhibitors significantly reduce cardiovascular events and heart failure risk in older adults with type 2 diabetes compared to DPP-4 inhibitors.

Dr. Brett Osborn, a Florida neurosurgeon who often prescribes GLP-1 RAs to his patients, believes that there is “no consistent causal relationship” between these medications and mental illness.

There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort ...

The likelihood for antibody-mediated rejection in lung transplant recipients was heightened with vs. without GLP-1 receptor agonist use, whereas the odds for mortality dropped with use, according ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor (DPP4i); 43,499 starting a sodium-glucose cotransporter 2 inhibitor ...